Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04287790 · ClinicalTrials.gov registry record

Promoting Medications for Alcohol Use Disorder on the General Medicine Service

A clinical trial, sponsored by Yale University.

Terminated
Registry status
67
Enrollment target

NCT04287790 is a clinical trial that was terminated before completion, run by Yale University. The registered enrollment target is 67 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04287790 was terminated before completion, sponsored by Yale University.

TERMINATED
Registry status
67 participants
Enrollment target

Study Summary

Medications for Alcohol use disorder (MAUD) (acamprosate, naltrexone, and disulfiram) remain underutilized despite guideline recommendations and rising alcohol-related morbidity and mortality. Alcohol use disorder (AUD)-related hospitalizations are opportunities to initiate MAUD, but optimal implementation strategies are unclear. We will complete a 6 month pilot implementation intervention involving audit and feedback, educational meetings, and academic detailing for health professionals at Yale New Haven Hospital to determine the impact on: 1) health professional satisfaction with intervention components, 2) health professional knowledge and attitudes about medications for alcohol use disorder, 3) receipt of medication among hospitalized patients diagnosed with an alcohol use disorder and 4) 30 day readmission among hospitalized patients with alcohol use disorder. Health professional satisfaction and knowledge with be assessed using a pre-post design and receipt of medications and 30 day readmission will be assessed using a interrupted time series design. We hypothesize health professional knowledge and attitudes about MAUD will be greater after the pilot intervention compared to before. We hypothesize receipt of MAUD will be greater after the pilot intervention compared to before. We hypothesize 30 day readmission will be less after the pilot intervention compared to before.

Interventions

  • BEHAVIORAL audit and feedback, educational meetings, and academic detailing to promote medication receipt
  • DRUG Acamprosate, naltrexone, or disulfiram

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2020-01-01
Est. Completion 2021-02-01

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT04287790

The ClinicalTrials.gov registry entry for NCT04287790 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which audit and feedback, educational meetings, and academic detailing to promote medication receipt is the first listed.

NCT04287790 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04287790 about?

NCT04287790 is a clinical study titled "Promoting Medications for Alcohol Use Disorder on the General Medicine Service". Medications for Alcohol use disorder (MAUD) (acamprosate, naltrexone, and disulfiram) remain underutilized despite guideline recommendations and rising alcohol-related morbidity and mortality. Alcohol use disorder (AUD)-related hospitalizations are opportunities to initiate MAUD, but optimal impleme...

What is the current status of trial NCT04287790?

This trial is currently terminated. The enrollment target is 67 participants. The study started on 2020-01-01. Estimated completion is 2021-02-01.

What interventions are being tested in trial NCT04287790?

The interventions under investigation include: audit and feedback, educational meetings, and academic detailing to promote medication receipt (BEHAVIORAL), Acamprosate, naltrexone, or disulfiram (DRUG).

Who is sponsoring clinical trial NCT04287790?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.